Re: Supplements for Neuropathy> take a look at ..... w w w .diabetic-talk.org/dpn.htm
Thanks. They recommends a cocktail of slow-released Lipoic Acid, EPO
and Vitamin C. Is the reason why EPO helps neuropathy well
established? Is the below related?
Choice of oils for essential fat supplements can enhance production of
abnormal metabolites in fat oxidation disorders.
Patients with mitochondrial long-chain fat oxidation deficiencies are
usually treated with diets containing reduced fat and increased
carbohydrate, at times via gastrostomy feeding. To ensure adequate
intake of essential fatty acids, supplements are provided to their
diets using commercially available oils. These oils contain large
quantities of non-essential fats that are preferentially oxidized and
produce disease-specific metabolites (acyl-CoA intermediates) due to
the genetic defect. This study describes the concentrations of these
intermediates as reflected by acylcarnitines as well as the %
contribution from each of four fatty acids: palmitate, oleate,
linoleate, and alpha-linolenate when incubated with fibroblasts from
patients with VLCAD, LCHAD, and trifunctional protein (TFP)
deficiencies. Palmitate and oleate produce the majority of disease-
specific acylcarnitines with these defective cell lines (79-94%)
whereas linoleate and linolenate produced less (6-21%). On average,
the amount of acylcarnitines decreased with increasing unsaturation
(C18:1>C18:2>C18:3:34%>11%>3%, respectively. This relationship may
reflect the "gatekeeper" role of carnitine palmitoyltransferase I (CPT
I). A diet comparison between Canola and a combination of Flax/Walnut
oils revealed that the latter, containing the least amount of non-
essential fats, reduced blood acylcarnitine levels by 33-36%. The
etiology of the severe peripheral neuropathy of TFP deficiency may
result from the unique metabolite, 3-keto-acyl-CoA, after conversion
to a methylketone via spontaneous decarboxylation. Essential fatty
acid supplementation with oils should consider these findings to
decrease production of disease-specific acyl-CoA intermediates. PMID:
17825594